Lotteries and Microphone Control: FDA's Tools of Public Order
This article was originally published in RPM Report
To keep the public sessions of advisory committees civil and on-point, FDA has rules of conduct and (recently revised) tools of conduct.
You may also be interested in...
FDA would be wise to prepare for a new round of active, emotive open public sessions after the impact of the public testimony at the Benlysta lupus drug review on November 16. It’s been a long-time since a public session has had such a direct impact on creating a pro-approval atmosphere at a committee meeting.
A lot of people spent a lot of time at FDA working on a proposal for a class-wide opioid REMS: at least 70 people worked on the project over the past 18 months. When an FDA advisory committee considered the plan, though, a very brief statement by a former committee chair may have helped undo a lot of that work.
A year ago, Congress sent FDA two very clear, somewhat contradictory messages: Hold more advisory committee meetings, but without the use of many expert panelists used in the past. The result is a system that is stretched to the limits.